Jonathan Wosen

2 days ago | statnews.com | Casey Ross |Jonathan Wosen

She is serving an 11-year prison sentence for misleading investors and is barred from participating in federal health programs for 90 years. But Elizabeth Holmes’ dream of a diagnostic testing revolution is once again the talk of health care. The emergence of Haemanthus, a company formed by Holmes’ partner, Billy Evans, triggered a mix of shock, anger, and rueful skepticism on Monday, as one of health care’s most infamous frauds morphed into a new form, with fresh capital behind it.

1 week ago | statnews.com | Jonathan Wosen |Jason Mast

The National Institutes of Health Clinical Center, billed as the nation’s largest hospital devoted solely to medical research, is struggling to carry out its mission of running clinical trials for the hardest-to-treat diseases amid growing disruptions from the Trump administration. Fewer patients are being treated, and some trials are lagging months behind due to reduced staffing and uncertainty, according to STAT interviews with 11 staff members and researchers affiliated with the center.

1 week ago | statnews.com | Jonathan Wosen

PALO ALTO, Calif. — At an annual meeting usually focused on the industry’s future, life science leaders couldn’t help but grapple — 100 days into President Trump’s second term — with a present clouded by uncertainty. At Stanford’s Drug Discovery Symposium, biotech bigwigs spoke openly this week about how the scientific ecosystem that trains the industry’s workforce and produces many of the discoveries companies later turn into new drugs and diagnostics is now in jeopardy.

2 weeks ago | statnews.com | Jonathan Wosen

The National Institutes of Health on Friday announced six acting directors to run institutes, many to fill vacancies created by the ouster of predecessors as part of the Trump administration’s unprecedented reshaping of federal scientific agencies.

2 weeks ago | statnews.com | Jonathan Wosen

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient survival — the gold standard outcome of any cancer study. The drug, ivonescimab, was approved for previously untreated patients with non-small cell lung cancer who had detectable levels of PD-L1, a protein that tamps down immune responses.